53616-34-5

Upstream product

• 123617-80-1 2-(furan-3-yl)acetic acid 
• 67364-02-7 3-ethenylfuran 
• 4412-91-3 furan-3-methanol 
• 488-93-7 3-Furoic acid 
• 75-21-8 oxirane 
• 22037-28-1 3-bromofurane 
• 117770-26-0 (E)-3-((S)-2,2-Dimethyl-[1,3]dioxolan-4-yl)-4-methoxy-4-phenylsulfanyl-but-2-enoic acid ethyl ester 
• 117770-27-1 (E)-3-((S)-2,2-Dimethyl-[1,3]dioxolan-4-yl)-4-methoxy-4-phenylsulfanyl-but-2-en-1-ol 
• 117770-26-0 ethyl (Z,E)-(4R)-4,5-isopropylidenedioxy-3-<(RS)-(methoxy)(phenylthio)methyl>-2-pentenoate 
• 117770-27-1 (Z,E)-(4R)-4,5-isopropylidenedioxy-3-<(RS)-(methoxy)(phenylthio)methyl>-2-penten-1-ol 
• 14497-29-1 3-(chloromethyl)furan 
• 498-60-2 furan-3-carboxaldehyde 
• 117770-28-2 2-Furan-3-yl-2-phenylsulfanyl-ethanol 
• 68913-67-7 furan-3-yl-acetonitrile 

Downstream Products

• 98126-47-7 Toluene-4-sulfonic acid 2-furan-3-yl-ethyl ester 
• 89861-16-5 2-(2-Phenylsulfanyl-furan-3-yl)-ethanol 
• 98126-46-6 2-(3-furyl)-1-bromoethane 
• 82462-67-7 (+)-(4aS,8aS)-4-[2-(3-furyl)ethyl]-4a,5,6,7,8,8a-hexahydro-3,4a,8,8-tetramethylnaphthalen-2(1H)-one 
• 59805-78-6 (-)-5R,6R-microcionin-2 
• 183620-23-7 (4R)-(+)-3-[2-(3-furyl)ethyl]-4-methylcyclohex-2-en-1-one 
• 183620-22-6 [(3S,4R)-3-(2-Furan-3-yl-ethyl)-4-methyl-cyclohex-1-enyloxy]-trimethyl-silane 
• 183620-24-8 [(3R,4R)-3-(2-Furan-3-yl-ethyl)-3,4-dimethyl-cyclohex-1-enyloxy]-trimethyl-silane 
• 89861-18-7 2-(2-Phenylsulfanyl-5-trimethylsilanyl-furan-3-yl)-ethanol 
• 89861-17-6 2-Phenylsulfanyl-5-trimethylsilanyl-3-(2-trimethylsilanyloxy-ethyl)-furan 
• 1393904-45-4 C₁₃H₁₄O₂S 
• 98126-67-1 1-(hydroxymethyl)-3-<2-(3-furyl)ethyl>-1-cyclohexene 
• 98126-72-8 1-(1-hydroxyethyl)-3-<2-(3-furyl)ethyl>-1-cyclohexene 
• 98126-70-6 3-<2-(3-furyl)ethyl>-1-cyclohexene-1-carboxaldehyde 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

A formal synthesis of aflatoxin B2: a Doetz benzannulation approach

A Doetz benzannulation reaction has been utilized in the synthesis of the furo[2,3-b]furan core of aflatoxin B2.

A new route to 2,7- and 7-functionalized labdanes

A new route for the synthesis of 2,7- and 7-functionalized labdanes starts from (R)-carvone (1). 11-Nordrim-7-en-9-one (15) is an appropriate starting material for the total synthesis of hispanone (21), a biologically active furolabdane isolated from the

The first enantioselective synthesis of (-)-microcionin 2

An approach known to give regiospecific and stereospecific reactions has been applied to the enantioselective synthesis of the natural (-)-microcionin 2 (1), a prototype of trans relationship of the methyl groups on the furanosesquiterpenes.

CHIRAL PRECURSORS FOR SYNTHESES OF FURANOTERPENES

The synthesis of (2S,4R,5R) and (2R,4R,5R)-2-(3-furyl)-4,5-isopropylidenedioxytetrahydrofuran (4 and 5) and (2S,4R,5S)-5-ethoxy-2-(3-furyl)-4-hydroxytetrahydrofuran (37) from "diacetone glucose" (6) is described.A new approach to 1-(R) and 1-(S)-(3-furyl)

SYNTHESIS OF OPTICALLY PURE 1-(3-FURYL)-1,2-DIHYDROXYETHANE DERIVATIVES

The synthesis of the enantiomerically pure 1-(3-furyl)-1,2-dihydroxyethane derivatives 1-(R), 2-(R), 3-(S) and 3-(R) is described.